 So we'll have to wait for those results. But it sounds very promising. Is the process you're using adaptable to other brain diseases where, I don't know, there might be other proteins which you'd like to regulate, things like Alzheimer's, I don't know if Parkinson's or a disease like that might be appropriate for this kind of approach?